Following people with pacemakers to see how atrial fibrillation develops
Follows adults with dual-chamber pacemakers to see how atrial fibrillation changes over time.
Plain-language title generated from the registry record
Registry title: PACE-AF: Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation
Key facts
- Where
- Tver', RussiaSee the site
Where in Russia
- Tver State Medical University Clinical CenterTver', RussiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ilya Lukin
- Trial code
- NCT07279207
- Record updated
- 12 December 2025
- Original description
PACE-AF is a prospective, observational patient registry designed to evaluate the impact of pacemaker algorithms on atrial fibrillation (AF) incidence, progression, and clinical outcomes in patients implanted with dual-chamber pacemakers. The registry aims to include 400-500 patients with longitudinal follow-up. Primary outcomes are progression to permanent AF and all-cause mortality. Secondary outcomes include quality of life, hospitalization, and cardiovascular events.Read full original descriptionShow less
Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation (PACE-AF)
PACE-AF is a prospective, observational patient registry designed to evaluate the impact of pacemaker algorithms on atrial fibrillation (AF) incidence, progression, and clinical outcomes in patients implanted with dual-chamber pacemakers. The registry aims to include 400-500 patients with longitudinal follow-up. Primary outcomes are progression to permanent AF and all-cause mortality. Secondary outcomes include quality of life, hospitalization, and cardiovascular events.
Inclusion: • Age ≥ 18 years; Implantation of a dual-chamber permanent pacemaker; Ability to provide informed consent; Willingness to participate in long-term follow-up.
Exclusion: • Single-chamber pacemaker or Cardiac Resynchronization Therapy device at baseline; Life expectancy < 1 year due to non-cardiac comorbidities; Inability to comply with follow-up visits or device interrogation; Participation in another clinical trial that could interfere with study endpoints.